The first generic alternative to Roche's oral drug for influenza, Xofluza, has been approved by the FDA and should be ...

Google AI Overviews are a feature within Google Search that uses large language models (LLMs), specifically Google’s Gemini ...

Biogen has dipped its toe into the M&A waters once again, agreeing to buy San Diego-based RayThera for up to $1 billion in ...

Two AI large language models (LLMs) have shown they can match and even surpass doctors in virtual testing, although their ...

Moderna is hoping to launch three new vaccines in the next couple of years – including a flu shot that will come in front of ...

Details are starting to emerge of last week's cyberattack on Novo Nordisk, which now appears to have been a $25 million ...

The FDA refused to accept uniQure's filing for AMT-130 last November, and earlier this year the Dutch biotech said it had ...

This article was developed and funded by Gilead Sciences Ltd. For decades, the UK life sciences sector has been the jewel in ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Andrew Cavey, CEO of ITM, about current and future ...

The late-stage MonumenTAL-3 trial of Talvey (talquetamab), given in combination with J&J and Genmab's anti-CD38 antibody ...

Men with a particular form of prostate cancer now have a targeted treatment for the first time, thanks to FDA approval of a ...

Poolbeg Pharma is preparing to start a clinical trial of a drug that aims to block a life-threatening side effect of cancer ...